Company intelligence / Profile preview
Biofabri
O Porriño, Pontevedra, Spainbiofabri.es ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MTBVAC, their most advanced vaccine candidate against tuberculosis, is currently in Phase 3 clinical trials. It is the only live-attenuated M. tuberculosis vaccine evaluated in clinical trials that has demonstrated safety, efficacy, and immunogenicity in both preclinical and clinical studies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Classic vaccinesGenetically engineered live attenuated vaccinesSubunit vaccines (recombinant protein)RNA and DNA Vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
IAVI
Beyond the preview
Go deeper on Biofabri.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biofabri.